⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16486907 | 0.77 | — | — | |
| SCHEMBL385475 | 0.67 | — | — | |
| SCHEMBL65155 | 0.62 | — | — | |
| SCHEMBL5819277 | 0.62 | THRB (0.39) | — | |
| SCHEMBL55128 | 0.62 | — | — | |
| SCHEMBL7156637 | 0.62 | THRB (0.39) | — | |
| SCHEMBL31990 | 0.62 | — | — | |
| SCHEMBL20472787 | 0.62 | THRB (0.39) | — | |
| SCHEMBL21912725 | 0.61 | — | — | |
| SCHEMBL21751884 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858641-B2 | melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-7189727-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2007-03-13 | — | — | US | claimed |
| EP-1385823-B1 | GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS | CHIRON CORP (US) | 2006-12-13 | — | — | EP | claimed |
| US-6960582-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20050124652-A1 | Guanidino compounds | BOYCE RUSTUM (US) | 2005-06-09 | — | — | US | claimed |
| US-20050038027-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2005-02-17 | — | — | US | claimed |
| US-20040248895-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2004-12-09 | — | — | US | claimed |
| EP-1478626-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-6716840-B2 | AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES | CHIRON CORPORATION | 2004-04-06 | — | — | US | claimed |
| US-20040024211-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2004-02-05 | — | — | US | claimed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | claimed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| CN-109996839-A | Polyimide film | 宇部兴产株式会社 | 2019-07-09 | — | — | CN | disclosed |
| CN-109923148-A | Polyimides and the flexible device for having used the polyimides | 宇部兴产株式会社 | 2019-06-21 | — | — | CN | disclosed |
| US-7858631-B2 | Substituted pyrido [2,3-d] pyrimidinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1082120-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI Pharmaceuticals, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999062518-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |